Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05552118
Other study ID # CLTD5764
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 18, 2024
Est. completion date December 2025

Study information

Verified date May 2024
Source Cochlear
Contact PRS Specialist, Clinical Affairs
Phone +61 2 9428 6555
Email cltd-prs-admin@cochlear.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to assess the real-world effectiveness of managing participants within the first year post-activation (between 3 and 12 months) using Cochlear's Remote Care (Remote Check and Remote Assist), as compared with standard in-clinic management. The study captures also the time and costs associated with both models of care to quantify the potential costs savings and efficiency gains possible with delivering Cochlear Implant (CI) aftercare remotely.


Recruitment information / eligibility

Status Recruiting
Enrollment 148
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged 18 years or older (no upper age limit) - Post-lingually deafened - Unilaterally implanted with the CI600 Series (CI612, CI622, CI632),CI500 Series (CI512, CI522, CI532) or Freedom Series (CI24RE(CA),CI24RE(ST), CI422) - Currently using a Nucleus 7 (CP1000) or Kanso 2 (CP1050) Sound Processor (or latest compatible Sound Processor) - 3 months, +/- 2 weeks, experience with a cochlear implant (post-activation) at the time of baseline measurements - Owner of a compatible Smart Phone - Fluent in the languages used for the study, as determined by the investigator - Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm - Willing and able to provide written informed consent Exclusion Criteria: - Patient has a MAP incompatible with Master Volume, Bass and Treble (MVBT) programming: - Non-monopolar MAPs (bipolar, common ground, variable mode) - Dynamic range of <10 Comfortable Level (CL) - Hybrid mode enabled - Pulse widths >100 µs - 10 or more electrodes turned off - Patient has on-going fluctuations in MAP Threshold levels (Ts) and Comfort levels (Cs) and/or impedances - Patient requires frequent individual channel measurements and/or measurements without the use of live-stimulation - Score below 3 on the screening subset of questions from the Mobile Device Proficiency Questionnaire (MDPQ) - Abnormal cochlea anatomy and/or facial nerve stimulation - Additional disabilities that would prevent participation in evaluations, including significant visual impairment and/or dexterity issues - Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator - Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling - Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation - Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cochlear™ Remote care
Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review. Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit.
Standard of care
Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
Device:
Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)
CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)

Locations

Country Name City State
Belgium UZ Gent Gent
Belgium UZ Leuven Leuven
Italy University of Bari "A. Moro" UOC Otorinolaringoiatria Universitaria Bari
Italy Azienda Ospedale Università di Padova Padova
Netherlands Academisch Ziekenhuis Maastricht Maastricht
Netherlands Radboud University Medical Centre Nijmegen Nijmegen
United Kingdom Queen Elizabeth Hospital Audiology Centre - University Hospital Birmingham Birmingham
United Kingdom Auditory Implant Centre, Glan Clwyd Hospital Bodelwyddan
United Kingdom St George's Hospital London
United Kingdom St Thomas' Hospital London

Sponsors (3)

Lead Sponsor Collaborator
Cochlear Avania, QbD Clinical

Countries where clinical trial is conducted

Belgium,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in patient reported hearing ability in daily life measured with the SSQ12 (Speech, Spatial and Qualities of Hearing Scale) questionnaire between month 3 (baseline) and month 12 post-activation Measuring change of speech, spatial and hearing experiences (12 items). Each item is scored on a scale of 0 to 10 where 0 corresponds to "complete inability or complete absence of a quality" and 10 to "complete ability or complete presence of an ability". The score of a participant is determined as the mean of the 12 items. Higher scores indicate less hearing disability 3 months post-activation (baseline) and 12 months post-activation
Secondary Mean change in speech recognition score for an open-set word recognition measure in quiet between 3 months post-activation (baseline) and 12 months post-activation The test is done using phonetically balanced words and scores are recorded as % correct words. Higher scores indicate a better outcome. 3 months post-activation (baseline) and 12 months post-activation
Secondary Mean change in speech recognition score for sentences in adaptive noise between 3 months post-activation (baseline) and 12 months post-activation The test is done using validated lists of phonetically balanced sentences. The noise is kept constant at 65 decibel (dB) Sound Pressure Level (SPL), and the speech is adapted stepwise to establish the speech-to-noise ratio (SNR) providing a 50% level of understanding. Lower scores indicate a better outcome. 3 months post-activation (baseline) and 12 months post-activation
Secondary Descriptive summaries of clinic time and resource utilisation incurred between 3 months and 12 months post-activation assessed via a custom questionnaire. 3 months post-activation (baseline) and 12 months post-activation
Secondary Descriptive summaries of time and costs incurred by participants between 3 months and 12 months post-activation via a custom questionnaire 3 months post-activation (baseline) and 12 months post-activation
Secondary Participant satisfaction measured with the Client Satisfaction Questionnaire (CSQ)-8 at 12 months post-activation Measuring satisfaction of participants with the healthcare service (8 questions). Each item is scored using a 4-point Likert scale with 1 always indicating a negative response and 4 a positive response. A total higher score indicates higher satisfaction 12 months post-activation
Secondary Participant empowerment measured with the Patient Activation Measure (PAM), at 12 months post-activation Evaluating the knowledge, skills, beliefs, and behaviours that participants have for self-management of their long-term health condition (13 items). Each item is scored on a 4-point likert scale from 1 (strongly disagree) to 4 (strongly agree). The overall score is calculated and normalized to a 100-point scale. Higher scores indicate greater levels of activation. 12 months post-activation
See also
  Status Clinical Trial Phase
Recruiting NCT04696835 - fNIRS in Pediatric Hearing Aids N/A
Completed NCT03662256 - Reducing Childhood Hearing Loss in Rural Alaska Through a Preschool Screening and Referral Process Using Mobile Health and Telemedicine N/A
Completed NCT04602780 - Evaluating the Revised WORQ in CI Users
Completed NCT03723161 - Evaluation of the Ponto Bone Anchored Hearing System in a Pediatric Atresia Population
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03428841 - Audiovisual Assessment After Dural Puncture During Epidural Placement in Obstetric Patients N/A
Completed NCT04559282 - Home Test of New Sound Processor N/A
Enrolling by invitation NCT03345654 - Individually-guided Hearing Aid Fitting
Completed NCT06016335 - MRI-based Synthetic CT Images of the Head and Neck N/A
Completed NCT05165121 - Comparison of Hearing Aid Fitting Outcomes Between Self-fit and Professional Fit for MDHearing Smart Hearing Aids N/A
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Terminated NCT02294812 - Effects of Cognitive Training on Speech Perception N/A
Completed NCT04622059 - AUditive Direct In-utero Observation (AUDIO): Prenatal Testing of Congenital Hypoacusis N/A
Recruiting NCT02558478 - Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing N/A
Withdrawn NCT02740322 - Validating the Hum Test N/A
Completed NCT01963104 - Community-Based Kiosks for Hearing Screening and Education N/A
Completed NCT01892007 - Evaluation of Cogmed Working Memory Training for Adult Hearing Aid Users N/A
Completed NCT01857661 - The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial N/A
Withdrawn NCT01223638 - The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism N/A